Inhibition of Gli1 results in altered c-Jun activation, inhibition of cisplatin-induced upregulation of ERCC1, XPD and XRCC1, and inhibition of platinum-DNA adduct repair

Oncogene

Volumn 31, Issue 44, 2012, Pages 4718-4724

  Kudo, K ^a   Gavin, E ^a   Das, S ^a   Amable, L ^a   Shevde, L A ^a   Reed, E ^a  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

Author keywords

cisplatin; ERCC1; Gli1; ovarian cancer; XPD; XRCC1

Indexed keywords

ALPHA TUBULIN; CISPLATIN; CYCLOPAMINE; DNA; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; MESSENGER RNA; PROTEIN C JUN; SERINE; SHORT HAIRPIN RNA; SONIC HEDGEHOG PROTEIN; THREONINE; TRANSCRIPTION FACTOR GLI1; TRANSCRIPTION FACTOR GLI2; XRCC1 PROTEIN;

ARTICLE; ATOMIC ABSORBANCE SPECTROMETRY; CELL KILLING; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DNA ADDUCT; DNA REPAIR; FEMALE; HUMAN; HUMAN CELL; IC 50; MAXIMUM INHIBITORY CONCENTRATION; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN PHOSPHORYLATION; SPECTROMETRY; UPREGULATION;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CISPLATIN; DNA ADDUCTS; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GENE SILENCING; HUMANS; ONCOGENE PROTEINS; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-JUN; RNA INTERFERENCE; TRANS-ACTIVATORS; XERODERMA PIGMENTOSUM GROUP D PROTEIN;

ERINACEIDAE;

EID: 84869091778     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2011.610     Document Type: Article

References (48)

1. Reed E. Cisplatin, Carboplatin, and Oxaliplatin. In: Chabner BA, Longo DL (eds). Cancer Chemotherapy and Biotherapy: Principles and Practice 4th Edn. Lippincott, Williams & Wilkins: Philadelphia, 2006, pp 332-343.
2. Reed E. Cisplatin and platinum analogs. In: DeVita VT, Rosenberg SA, Lawrence TS (eds). Cancer Principles and Practice of Oncology 8th Edn. Lippincott, Williams, and Wilkins: Philadelphia, 2008, pp 419-426.
3. Reed E. ERCC1 and clinical resistance to platinum-based therapy. Clin Cancer Res 2005; 11: 6100-6102. (Pubitemid 41262934)
4. Reed E. ERCCI measurements in clinical oncology. N Engl Med 2006; 355: 1054-1055.
5. Reed E. DNA damage and repair in clinical oncology: an overview. Clin Cancer Res 2010; 16: 4511-4516.
6. Reed E. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998; 27: 187-201. (Pubitemid 29025469)
7. Reed E. Platinum-DNA adduct, nucleotide excision repair, and platinum based anti-cancer chemotherapy. Cancer Treat Rev 1998; 24: 331-344. (Pubitemid 28537769)
8. Li Q, Gardner K, Zhang L, Tsang B, Bostick-Bruton F, Reed E. Cisplatin induction of ERCC1 mRNA expression in A2780/CP70 human ovarian cancer cells. J Biol Chem 1998; 273: 23419-23425. (Pubitemid 28417531)
9. Li Q, Bostick-Bruton F, Reed E. Modulation of ERCC-1 mRNA expression by pharmacological agents in human ovarian cancer cells. Biochem Pharmacol 1999; 57: 347-353.
10. Mimnaugh EG, Yunmbam MK, Li Q, Bonvini P, Hwang SG, Trepel J et al. Proteasome inhibitors prevent cisplatin-DNA adduct repair and potentiate cisplatin-induced apoptosis in ovarian carcinoma cells. Biochem Pharmacol 2000; 60: 1343-1354.
11. Li Q, Tsang B, Gardner K, Bostick-Bruton F, Reed E. Phorbol ester exposure activates an AP-1 associated increase in ERCC1 mRNA expression in human ovarian cancer cells. Cell Mol Life Sci 1999; 55: 456-466. (Pubitemid 29178884)
12. Laner-Plamberger S, Kaser A, Paulischta M, Hauser-Kronberger C, Eichberger T, Frischauf AM. Cooperation between Gli and Jun enhances transcription of Jun and selected Gli target genes. Oncogene 2009; 28: 1639-1651.
13. Theunissen JW, de Sauvage FJ. Paracrine Hedgehog signaling in cancer. Cancer Res 2009; 69: 6007-6010.
14. Liao X, Siu MKY, Au Christy WH, Wong ESY, Chan HY, Ip PPC et al. Aberrant activation of hedgehog signaling pathway in ovarian cancers: effect on prognosis, cell invasion and differentiation. Carcinogenesis 2009; 30: 131-140.
15. Bhattacharya R, Kwon J, Ali B, Wang E, Patra S, Shridhar V et al. Role of hedgehog signaling in ovarian cancer. Clin Cancer Res 2008; 14: 7659-7666.
16. Raivich G. c-Jun expression, activation and function in neural cell death, inflammation and repair. J Neurochem 2008; 107: 898-906.
17. Bonovich M, Olive M, Reed E, O'Connell B, Vinson C. Adenoviral delivery of A-FOS, an AP-1 dominant negative, selectively inhibits drug resistance in two human cancer cell lines. Cancer Gene Ther 2002; 9: 62-70. (Pubitemid 34052855)
18. Parker RJ, Eastman A, Bostick-Bruton F, Reed E. Acquired cisplatin resistance in human ovarian cancer cells is associated with enhanced repair of cisplatin-DNA lesions and reduced drug accumulation. J Clin Invest 1991; 87: 772-777.
19. Zhen W, Link Jr CJ, O'Connor PM, Reed E, Parker RJ, Howell SB et al. Increased gene-specific repair of cisplatin interstand crosslinks in cisplatin resistant human ovarian cancer cells. Mol Cell Biol 1992; 87: 3689-3698.
20. Desouza LA, Sathanoori M, Kapoor R, Rajadhyaksha N, Gonzalez LE, Kottmann AH et al. Thyroid hormone regulates the expression of the sonic hedgehog signaling pathway in the embryonic and adult mammalian brain. Endocrinology 2011; 152: 1989-2000.
21. Sugahara F, Aota S, Kuraku S, Murakami Y, Takio-Ogawa Y, Hirano S et al. Involvement of Hedgehog and FGF signaling in the lamprey telencephalon: evolution of regionalization and dorsoventral patterning of the vertebrate forebrain. Development 2011; 138: 1217-1226.
22. Chang HH, Chen BY, Wu CY, Tsao ZJ, Chen YY, Chang CP et al. Hedgehog overexpression leads to the formation of prostate cancer stem cells with metastatic property irrespective of androgen receptor expression in the mouse model. J Biomed Sci 2011; 18: 6.
23. Song Z, Yue W, Wei B, Wang N, Li T, Guan L et al. Sonic hedgehog pathway is essential for maintenance of cancer stem-like cells in human gastric cancer. PLoS One. 2011; 6: e17687.
24. Rudin CM, Hann CL, Laterra J, Yauch RL, Callahan CA, Fu L et al. Treatment of medulloblastoma with hedgehog pathway inhibitor GDC-0449. N Engl J Med 2009; 361: 1173-1178.
25. Von Hoff DD, Korn R, Mousses S. Pancreatic cancer-could it be that simple? A different context of vulnerability. Cancer Cell 2009; 16: 7-8.
26. Von Hoff DD, LoRusso PM, Rudin CM, Reddy JC, Yauch RL, Tibes R et al. Inhibition of the hedgehog pathway in advanced basal-cell carcinoma. N Engl J Med 2009; 361: 1164-1172.
27. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Canc Inst 1992; 84: 1512-1517.
28. Dabholkar M, Vionnet JA, Bostick-Bruton F, Yu JJ, Reed E. mRNA Levels of XPAC and ERCC1 in ovarian tumor tissue correlates with response to platinum containing chemotherapy. J Clin Invest 1994; 94: 703-708. (Pubitemid 24251002)
29. Krivak TC, Darcy KM, Tian C, Bookman M, Gallion H, Ambrosone CB et al. Single nucleotide polypmorphisms in ERCC1 are associated with disease progression, and survival in patients with advanced stage ovarian and primary peritoneal carcinoma; A Gynecologic Oncology Group Study. Gynecol Oncol 2011; 22: 121-126.
30. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in Non-small-cell lung cancer. J Clin Oncol 2007; 25: 2747-2754. (Pubitemid 47123183)
31. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Domine M et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine chemotherapy in non-small cell lung cancer. Clin Cancer Res 2002; 8: 2286-2291. (Pubitemid 34753602)
32. Bellmunt J, Paz-Ares L, Cuello M, Cecere FL, Abiol S, Guillem V et al. Gene expression of ERCC1 as a novel prognostic marker in advanced bladder cancer patients receiving cisplatin-based chemotherapy. Ann Oncol 2007; 18: 522-528. (Pubitemid 46359633)
33. Metzger R, Leichman CG, Danenberg KD, Daneberg PV, Lenz HJ, Hayashi K et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1998; 16: 309-316. (Pubitemid 28041614)
34. Wei J, Zou Z, Qian X, Ding Y, Xie L, Sanchez JJ et al. ERCC1 mRNA levels and survival of advanced gastric patients treated with a modified FOLFOX regimen. Br J Cancer 2008; 98: 1398-1402. (Pubitemid 351543582)
35. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD et al. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001; 19: 4298-4304. (Pubitemid 33096777)
36. Altaha R, Liang X, Yu JJ, Reed E. ERCC-1 gene expression and platinum resistance. Int J Mol Med 2004; 14: 959-970.
37. Kim MK, Cho KJ, Kwon GY, Park SI, Kim YH, Kim JH et al. Patients with ERCC1-negative locally advanced esophageal cancers may benefit from preoperative chemoradiotherapy. Clin Cancer Res 2008; 14: 4225-4231.
38. Verhoeven EEA, van Kesteren M, Moolenaar GF, Visse R, Goosen N. Catalytic sites for 30 and 50 incision of Escherichia coli nucleotide excision repair are both located in UvrC. J Biol Chem 2000; 275: 5120-5123. (Pubitemid 30108913)
39. Westerveld A, Hoeijmakers JH, van Duin M, de Wit J, Odijk H, Pastink A et al. Molecular cloning of a human DNA repair gene. Nature 1984; 310: 425-429. (Pubitemid 14051113)
40. Xu H, Swoboda I, Bhalla PL, Sijbers AM, Zhao C, Ong EK et al. Plant homologue of human excision repair gene ERCC1 points to conversation of DNA repair mechanisms. Plant J 1998; 13: 823-829. (Pubitemid 28178643)
41. Dabholkar M, Bostick-Bruton F, Weber C, Egwuagu C, Bohr VA, Reed E. Expression of excision repair genes in non-malignant bone marrow from cancer patients. Mutat Res 1993; 293: 151-160. (Pubitemid 23016407)
42. Dabholkar MD, Berger MS, Vionnet JA, Egwuagu C, Silber JR, Yu JJ et al. Malignant and non-malignant brain tissues differ in their mRNA expression patterns for ERCC1 and ERCC2. Cancer Res 1995; 55: 1261-1266.
43. Dabholkar MD, Berger MS, Vionnet JA, Overton L, Bostick-Bruton F, Yu JJ et al. Comparative analyses of relative ERCC3 and ERCC6 mRNA levels in gliomas and adjacent non-neoplastic brain. Mol Carcinog 1996; 17: 1-7. (Pubitemid 26379341)
44. Dabholkar M, Thornton K, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Increased mRNA levels of XPB and CSB without increased mRNA levels of MDR1 or MT-II in platinum-resistant human ovarian cancer tissues. Biochem Pharmacol 2000; 60: 1611-1619.
45. Reed E, Yu JJ, Davies A, Gannon J, Armentrout SL. Clear cell tumors have higher mRNA levels of ERCC1 and XPB than other histological types of epithelial ovarian cancer. Clin Cancer Res 2003; 9: 5299-5305. (Pubitemid 37413583)
46. Zhong Z, Thornton K, Reed E. Computer based analyses of the 50-flanking regions of selected genes involved in the nucleotide excision repair excision complex. Int J Oncol 2000; 17: 375-380.
47. Das S, Harris LG, Metge BJ, Liu S, Riker AI, Samant RS et al. The Hedgehog pathway transcription factor, Gli1 promotes malignant behavior of cancer cells by upregulating osteopontin. J Biol Chem 2009; 284: 22888-22897.
48. Reed E, Sauerhoff S, Poirier MC. Quantitation of platinum-DNA binding in human tissues following therapeutic levels of drug exposure-A novel use of graphite furnace spectrometry. Atomic Spectroscopy 1988; 9: 93-95.